Pancreatic Cancer Research

ResearcherChinese Academy of Medical Sciences & Peking Union Medical CollegeNo recent work listed

Tianxiao Wang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-4038-2050; OpenAlex author ID A5101930340. Sources: OpenAlex.

Their work

Papers
8 (first author 2, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
18
Papers, trials and grants by year

2013: 1 paper · 2014: 5 papers · 2015: none · 2016: 1 paper · 2017: none · 2018: none · 2019: none · 2020: none · 2021: none · 2022: none · 2023: 1 paper

Papers 8

  1. Stage II Pancreatic Adenocarcinoma after Endovascular Repair of Abdominal Aortic Aneurysm: A Case Report and Literature Review. Co-author DOI 10.3390/jcm12020443↗
  2. PIM-1 contributes to the malignancy of pancreatic cancer and displays diagnostic and prognostic value. Co-author DOI 10.1186/s13046-016-0406-z↗
  3. Alteration of the intrinsic apoptosis pathway is involved in Notch-induced chemoresistance to gemcitabine in pancreatic cancer. Co-author DOI 10.1016/j.arcmed.2013.10.001↗
  4. Insulin-like growth factor 1 receptor (IGF-1R) as a target of MiR-497 and plasma IGF-1R levels associated with TNM stage of pancreatic cancer. First author DOI 10.1371/journal.pone.0092847↗
  5. CHIP is a novel tumor suppressor in pancreatic cancer through targeting EGFR. Co-author DOI 10.18632/oncotarget.1890↗
  6. MiR-497 downregulation contributes to the malignancy of pancreatic cancer and associates with a poor prognosis. First author DOI 10.18632/oncotarget.2184↗
  7. PIM kinases: an overview in tumors and recent advances in pancreatic cancer. Co-author DOI 10.2217/fon.13.229↗
  8. Notch1 contributes to chemoresistance to gemcitabine and serves as an unfavorable prognostic indicator in pancreatic cancer. Co-author DOI 10.1007/s00268-013-2010-0↗

Closest collaborators

The 18 strongest of 18 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Lei You · 7 shared papers, 2013–2016 · strength 0.31
  2. Taiping Zhang · 6 shared papers, 2014–2016 · strength 0.28
  3. Jianwei Xu · 5 shared papers, 2014–2016 · strength 0.23
  4. Zihuan Zhang · 1 shared paper, 2023 · strength 0.22
  5. Wenquan Niu · 1 shared paper, 2023 · strength 0.22
  6. Zhiying Yang · 1 shared paper, 2023 · strength 0.22
  7. Li Zhou · 5 shared papers, 2013–2016 · strength 0.21
  8. Yupei Zhao · 4 shared papers, 2014–2016 · strength 0.19
  9. Hong Shu · 4 shared papers, 2013–2014 · strength 0.16
  10. Zhe Cao · 3 shared papers, 2014–2016 · strength 0.13
  11. Yu-Pei Zhao · 3 shared papers, 2013–2014 · strength 0.13
  12. Hua Huang · 2 shared papers, 2014–2016 · strength 0.09
  13. Xiao Hong Du · 2 shared papers, 2013–2014 · strength 0.08
  14. Ge Chen · 2 shared papers, 2013–2014 · strength 0.08
  15. Guangbing Xiong · 1 shared paper, 2016 · strength 0.05
  16. Shanglong Liu · 1 shared paper, 2014 · strength 0.04
  17. Min Li · 1 shared paper, 2014 · strength 0.04
  18. Jingxuan Yang · 1 shared paper, 2014 · strength 0.04

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.